Original Article

You have full text access to this OnlineOpen article

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model†‡

  1. Sammy Saab1,2,§,*,
  2. Douglas R. Hunt3,
  3. Michael A. Stone1,
  4. Amy McClune1,2,
  5. Myron J. Tong1,2,4

Article first published online: 23 MAR 2010

DOI: 10.1002/lt.22072

Issue

Liver Transplantation

Liver Transplantation

Volume 16, Issue 6, pages 748–759, June 2010

Additional Information

How to Cite

Saab, S., Hunt, D. R., Stone, M. A., McClune, A. and Tong, M. J. (2010), Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model. Liver Transpl, 16: 748–759. doi: 10.1002/lt.22072

Author Information

  1. 1

    Departments of Medicine, University of California at Los Angeles, Los Angeles, CA

  2. 2

    Department of Surgery, University of California at Los Angeles, Los Angeles, CA

  3. 3

    Harbor-UCLA Medical Center, Torrance, CA

  4. 4

    Huntington Medical Research Institutes, Pasadena, CA

  1. §

    Telephone: 310-206-6705; FAX: 310-206-4197

*Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, CA 90095

  1. †

    No author has a conflict of interest to declare with respect to the content of this study. No part of this study was funded by the pharmaceutical industry.

  2. ‡

    See Editorial on Page 697

Publication History

  1. Issue published online: 25 MAY 2010
  2. Article first published online: 23 MAR 2010
  3. Accepted manuscript online: 23 MAR 2010 12:00AM EST
  4. Manuscript Accepted: 10 MAR 2010
  5. Manuscript Received: 7 OCT 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (454K)

REFERENCES

  • 1
    Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004; 10: 886-897.
    Direct Link:
  • 2
    Gringeri E, Vitale A, Brolese A, Zanus G, Boccagni P, Neri D, et al. Hepatitis C virus-related cirrhosis as a significant mortality factor in intention-to-treat analysis in liver transplantation. Transplant Proc 2007; 39: 1901-1903.
  • 3
    Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades. Ann Surg 2005; 241: 905-916.
  • 4
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
  • 5
    Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, Sanchez-Tapias JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56-63.
  • 6
    Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256.
    Direct Link:
  • 7
    Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-322.
  • 8
    Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836.
  • 9
    Tine F, Attanasio M, Russo F, Pagliaro L. A decade of trials of interferon-alpha for chronic hepatitis C: a meta-regression analysis. Contemp Clin Trials 2005; 26: 179-210.
  • 10
    Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-342.
    Direct Link:
  • 11
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
  • 12
    Everson GT, Balart L, Lee SS, Reindollar RW, Shiffman ML, Minuk GY, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008; 27: 542-551.
  • 13
    Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fountaine H, Pol S. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
  • 14
    Abergal A, Darcha C, Chevallier M, Ughetto S, Henquell C, Pol S, et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 2004; 16: 1219-1227.
  • 15
    Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
  • 16
    Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P. Fibrosis progression on hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-based therapy). Transplantation 2007; 15: 351-353.
  • 17
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
    Direct Link:
  • 18
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
  • 19
    Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, et al. Peginterferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484-491.
  • 20
    Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
  • 21
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
  • 22
    Piccioto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465.
  • 23
    Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD practice guidelines. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1373.
    Direct Link:
  • 24
    Everson GT, Kulig CC. Antiviral therapy for hepatitis C in the setting of liver transplantation. Curr Treat Options Gastroenterol 2006; 9: 520-529.
  • 25
    Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27: 1081-1085.
    Direct Link:
  • 26
    Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212.
  • 27
    Abergal A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat 2006; 13: 811-820.
    Direct Link:
  • 28
    Saab S, Ly D, Han SB, Lin RK, Rojter SE, Ghobrial RM, Busuttil RW. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002; 8: 449-457.
    Direct Link:
  • 29
    Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology 2008; 48: 1387-1395.
    Direct Link:
  • 30
    Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073-1079.
    Direct Link:
  • 31
    Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med 1982; 73: 883-888.
  • 32
    United Network for Organ Sharing. Transplants. http://www.unos.org. Accessed March 2010.
  • 33
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
  • 34
    Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldequer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413.
    Direct Link:
  • 35
    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-114.
  • 36
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-181.
  • 37
    Walter T, Dumortier J, Guillaud O, Hervieu V, Scoazec JY, Boillot O. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl 2007; 13: 294-301.
    Direct Link:
  • 38
    Iacob S, Cicinnati V, Hilgard P, Iacob RA, Gheorghe LS, Popescu I, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007; 84: 56-63.
  • 39
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247.
    Direct Link:
  • 40
    Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
    Direct Link:
  • 41
    Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9: 672-681.
    Direct Link:
  • 42
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
  • 43
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023.
  • 44
    Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alfa-2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-194.
  • 45
    Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166-173.
    Direct Link:
  • 46
    Biselli M, Andreone P, Gramenzi A, Lorenzini S, Loggi E, Bonvicini F, et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006; 38: 27-32.
  • 47
    Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, Neuhaus P. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43-47.
  • 48
    Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303-1307.
  • 49
    Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasa JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-728.
  • 50
    Centers for Medicare and Medicaid Services. Cost database 2009. http://www.cms.hhs.gov/apps/ama/license.asp?file=/HospitalOutpatientPPS/Downloads/CMS_1404_FC_OPPS_Offset_Amounts_by_APC.zip. Accessed March 2010.
  • 51
    Drug Topics Red Book 2009. Montvale, NJ: Medical Economics; 2009.
  • 52
    US Bureau of Labor Statistics. Overview of BLS statistics on inflation and prices. http://www.bls.gov/bls/infla tion.htm. Accessed March 2010.
  • 53
    Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100: 643-651.
    Direct Link:
  • 54
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.
    Direct Link:
  • 55
    Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-638.
    Direct Link:
  • 56
    Bonkovsky HL, Woolley JM, for the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264-270.
    Direct Link:
  • 57
    Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Vargas V, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 231-238.
  • 58
    Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  • 59
    Zimmerman T, Bocher WO, Biesterfeld S, Zimmerman A, Kanzler S, Greif-Higer G, et al. Efficacy of an escalating dose regimen of pegylated interferon alfa-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20: 583-590.
    Direct Link:
  • 60
    Fernandez I, Meneu JC, Colina F, Garcia I, Munoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805-1812.
    Direct Link:
  • 61
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alfa-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-59.
  • 62
    Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-1108.
    Direct Link:
  • 63
    Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transplant 2006; 6: 2348-2355.
    Direct Link:
  • 64
    Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Avellini C, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577-582.
    Direct Link:
  • 65
    Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: from a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359-365.
  • 66
    Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study of peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-1017.
  • 67
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355.
    Direct Link:
  • 68
    Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
  • 69
    Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
    Direct Link:
  • 70
    Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzi T, Fung J. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999; 230: 441-448.
  • 71
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674.
  • 72
    Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687.
    Direct Link:
  • 73
    Mukherjee S, Lyden E. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int 2006; 26: 529-535.
    Direct Link:
  • 74
    Mukherjee S, Lyden E. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Hepatogastroenterology 2006; 53: 561-565.
  • 75
    Wong JB, Bennett WG, Koff RS. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998; 280: 2088-2093.
  • 76
    Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48: 843-848.
  • 77
    Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 823-830.
  • 78
    Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-393.
  • 79
    Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975-983.
    Direct Link:
  • 80
    Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al., for the EUROHEP Group. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 619-625.
  • 81
    Arias E. United States Life Tables, 2007. Hyattsville, MD: National Center for Health Statistics; 2007.
  • 82
    Rufat P, Fourquet F, Conti F, Le Gales C, Houssin D, Coste J. Costs and outcomes of liver transplantation in adults: a prospective, 1-year, follow-up study. Transplantation 1999; 68: 76-83.
  • 83
    Salomon J, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
  • 84
    Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002; 37: 1625-1642.
    Direct Link:
  • 85
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 1-125.
  • 86
    Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat 2007; 14: 523-536.
    Direct Link:
  • 87
    Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014.
  • 88
    Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520-527.
    Direct Link:
  • 89
    Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259.
  • 90
    Henrion J, Libon E, De Maeght S, Deltenre P, Schapira M, Ghilain JM, et al. Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin. Gastroenterol Clin Biol 2003; 27: 534-539.
View Full Article (HTML) Get PDF (454K)